Unicycive Therapeutics (UNCY) Non-Current Assets (2021 - 2026)
Unicycive Therapeutics posted quarterly Non-Current Assets of $861000.0 for Q1 2026, up 43.26% year-on-year from $601000.0 in Q1 2025, and up 394.83% on a QoQ basis from $174000.0 in Q4 2025.
Unicycive Therapeutics (UNCY) has 6 years of Non-Current Assets data on file, last reported at $861000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets rose 43.26% year-over-year to $861000.0; the trailing twelve-month figure through Mar 2026 stood at $1.8 million (down 34.74% YoY), and the FY2025 full-year result was $174000.0, down 75.83% from the prior year.
- Non-Current Assets for Q1 2026 stood at $861000.0, up from $174000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $1.0 million in Q1 2023 and bottomed at $174000.0 in Q4 2022.
- The 5-year median for Non-Current Assets is $647000.0 (2024), against an average of $583235.3.
- The widest annual swing landed in 2023, when Non-Current Assets surged 355.17%; it then tumbled 75.83% in 2025.
- A 5-year view of Non-Current Assets shows it stood at $174000.0 in 2022, then soared by 355.17% to $792000.0 in 2023, then declined by 9.09% to $720000.0 in 2024, then sank by 75.83% to $174000.0 in 2025, then surged by 394.83% to $861000.0 in 2026.
- The last three Non-Current Assets figures came in at $861000.0 (Q1 2026), $174000.0 (Q4 2025), and $324000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | 861,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 861,000.00 |
| Dec 31, 2025 | 174,000.00 |
| Sep 30, 2025 | 324,000.00 |
| Jun 30, 2025 | 469,000.00 |
| Mar 31, 2025 | 601,000.00 |
| Dec 31, 2024 | 720,000.00 |
| Sep 30, 2024 | 833,000.00 |
| Jun 30, 2024 | 647,000.00 |
| Mar 31, 2024 | 709,000.00 |
| Dec 31, 2023 | 792,000.00 |
| Sep 30, 2023 | 873,000.00 |
| Jun 30, 2023 | 953,000.00 |
| Mar 31, 2023 | 1.02 Mn |
| Dec 31, 2022 | 174,000.00 |
| Sep 30, 2022 | 215,000.00 |
| Jun 30, 2022 | 256,000.00 |
| Mar 31, 2022 | 296,000.00 |
| Dec 31, 2021 | 333,000.00 |